Breathe Well Live Well
|
Teva's Reslizumab Delivers Clinically and Statistically Significant Reduction …
Wall Street Journal Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma … |
View full post on asthma – Google News
|
FDA approves Teva's QVAR with dose counter to treat asthma
Pharmaceutical Business Review The US Food and Drug Administration (FDA) has approved the use of Teva Pharmaceutical's QVAR (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients five years of age and older. |
View full post on asthma – Google News
|
Teva's DuoResp Spiromax receives EC marketing authorization for treatment of …
News-Medical.net Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the European Commission has granted marketing authorization for DuoResp Spiromax® for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) … Teva Gets Approval To Market DuoResp Spiromax In Europe |
View full post on asthma – Google News
|
Teva's DuoResp Spiromax gets positive CHMP opinion to treat asthma and COPD
Pharmaceutical Business Review DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid for the treatment of underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting … Teva's Symbicort generic backed for EU approval 10 new medicines recommended for approval in Europe |
View full post on asthma – Google News